Skip to main content
. 2023 Oct 16;28(6):571–580. doi: 10.1177/1358863X231199489

Figure 4.

Figure 4.

Rutherford categories of patients in the SAVAL trial at baseline and follow-up.

DES, drug-eluting stent; PTA, percutaneous transluminal angioplasty.